Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

1998 ◽  
Vol 41 (4) ◽  
pp. 281-291 ◽  
Author(s):  
Brigitte Tranchand ◽  
Gilles Catimel ◽  
Catherine Lucas ◽  
Marlis Sarkany ◽  
Gérard Bastian ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors ◽  
Reversal Agent ◽  
Resistance Reversal

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

2009 ◽  
Vol 66 (3) ◽  
pp. 441-448 ◽  
Author(s):  
E. Gabriela Chiorean ◽  
Srikar Malireddy ◽  
Anne E. Younger ◽  
David R. Jones ◽  
Mary-Jane Waddell ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Dose Escalation ◽  
Advanced Solid Tumors

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

2008 ◽  
Vol 63 (5) ◽  
pp. 903-910 ◽  
Author(s):  
Claire F. Verschraegen ◽  
Keith Skubitz ◽  
Adil Daud ◽  
Andrzej P. Kudelka ◽  
Ian Rabinowitz ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

scholarly journals Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

2010 ◽  
Vol 16 (9) ◽  
pp. 2656-2665 ◽  
Author(s):  
Quincy Chu ◽  
Alain Mita ◽  
Bahram Forouzesh ◽  
Anthony W. Tolcher ◽  
Gary Schwartz ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

scholarly journals Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

2010 ◽  
Vol 21 (2) ◽  
pp. 376-381 ◽  
Author(s):  
H.A. Wakelee ◽  
A. Patnaik ◽  
B.I. Sikic ◽  
M. Mita ◽  
N.L. Fox ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

2006 ◽  
Vol 12 (12) ◽  
pp. 3774-3781 ◽  
Author(s):  
Isa E.L.M. Kuppens ◽  
Eric Dansin ◽  
Henk Boot ◽  
Celine Feger ◽  
Sylvia Assadourian ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Dose Finding ◽  
Advanced Solid Tumors

Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors

2000 ◽  
Vol 18 (20) ◽  
pp. 3545-3552 ◽  
Author(s):  
Corinne Couteau ◽  
Marie-Laure Risse ◽  
Michel Ducreux ◽  
Florence Lefresne-Soulas ◽  
Alessandro Riva ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Topoisomerase I ◽  
Maximum Tolerated Dose ◽  
Hematologic Toxicity ◽  
Advanced Solid Tumors ◽  
Phase Ii Studies ◽  
Grade 3

PURPOSE: We conducted a phase I and pharmacokinetic study of docetaxel in combination with irinotecan to determine the dose-limiting toxicity (DLT), the maximum-tolerated dose (MTD), and the dose at which at least 50% of the patients experienced a DLT during the first cycle, and to evaluate the safety and pharmacokinetic profiles in patients with advanced solid tumors. PATIENTS AND METHODS: Patients with only one prior chemotherapy treatment (without taxanes or topoisomerase I inhibitors) for advanced disease were included in the study. Docetaxel was administered as a 1-hour IV infusion after premedication with corticosteroids followed immediately by irinotecan as a 90-minute IV infusion, every 3 weeks. No hematologic growth factors were allowed. RESULTS: Forty patients were entered through the following seven dose levels (docetaxel/irinotecan): 40/140 mg/m2, 50/175 mg/m2, 60/210 mg/m2, 60/250 mg/m2, 60/275 mg/m2, 60/300 mg/m2, and 70/250 mg/m2. Two hundred cycles were administered. Two MTDs were determined, 70/250 mg/m2 and 60/300 mg/m2; the DLTs were febrile neutropenia and diarrhea. Neutropenia was the main hematologic toxicity, with 85% of patients experiencing grade 4 neutropenia. Grade 3/4 nonhematologic toxicities in patients included late diarrhea (7.5%), asthenia (15.0%), febrile neutropenia (22.5%), infection (7.5%), and nausea (5.0%). Pharmacokinetics of both docetaxel and irinotecan were not modified with the administration schedule of this study. CONCLUSION: The recommended dose of docetaxel in combination with irinotecan is 60/275 mg/m2, respectively. At this dose level, the safety profile is manageable. The activity of this combination should be evaluated in phase II studies in different tumor types.

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors

2015 ◽  
Vol 33 (3) ◽  
pp. 594-602 ◽  
Author(s):  
Sarah A. Holstein ◽  
James C. Bigelow ◽  
Richard D. Olson ◽  
Robert E. Vestal ◽  
Gerald M. Walsh ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors ◽  
The Novel

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

2004 ◽  
Vol 10 (21) ◽  
pp. 7229-7237 ◽  
Author(s):  
Samir E. Witta ◽  
Daniel L. Gustafson ◽  
A. Scott Pierson ◽  
Alexander Menter ◽  
Scott N. Holden ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document